DNA Damage Response (DDR) Drugs in Oncology Analysis 2022: Coverage of 399 Companies Plus Partners Developing 835 DDR Drugs with 412 in Active Development Across 226 Different Targets – QNT Press Release4 years ago
Bispecific Molecules in Oncology Analytical Tool 2022: Coverage of 170+ Companies Plus Partners who are Developing 484 Bispecific Drugs with 411 in Active Development Across 177 Different Targets – QNT Press Release4 years ago
Global 2021 AI Venture Capital Investment Nears 2019 Historical High at US$22.3 Billion – QNT Press Release4 years ago
